Multiple sclerosis: Getting personal with induced pluripotent stem cells

A. Di Ruscio; F. Patti; R. S. Welner; D. G. Tenen; G. Amabile

doi:10.1038/cddis.2015.179

Multiple sclerosis: Getting personal with induced pluripotent stem cells

A. Di Ruscio
, F. Patti
, R. S. Welner
, D. G. Tenen
, G. Amabile

Research output: Contribution to journal › Review article › peer-review

Abstract

Human induced pluripotent stem (iPS) cells can be derived from lineage-restricted cells and represent an important tool to develop novel patient-specific cell therapies and research models for inherited and acquired diseases. Recently, patient-derived iPS cells, containing donor genetic background, have offered a breakthrough approach to study human genetics of neurodegenerative diseases. By offering an unlimited source of patient-specific disease-relevant cells, iPS cells hold great promise for understanding disease mechanisms, identifying molecular targets and developing phenotypic screens for drug discovery. This review will discuss the potential impact of using iPS cell-derived models in multiple sclerosis (MS) research and highlight some of the current challenges and prospective for generating novel therapeutic treatments for MS patients.

Original language	English
Article number	e1806
Journal	Cell Death and Disease
Volume	6
Issue number	7
DOIs	https://doi.org/10.1038/cddis.2015.179
Publication status	Published - 1 Jul 2015
Externally published	Yes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Access to Document

10.1038/cddis.2015.179

Cite this

@article{9a6b675e66d84b9da8b1724096269914,

title = "Multiple sclerosis: Getting personal with induced pluripotent stem cells",

abstract = "Human induced pluripotent stem (iPS) cells can be derived from lineage-restricted cells and represent an important tool to develop novel patient-specific cell therapies and research models for inherited and acquired diseases. Recently, patient-derived iPS cells, containing donor genetic background, have offered a breakthrough approach to study human genetics of neurodegenerative diseases. By offering an unlimited source of patient-specific disease-relevant cells, iPS cells hold great promise for understanding disease mechanisms, identifying molecular targets and developing phenotypic screens for drug discovery. This review will discuss the potential impact of using iPS cell-derived models in multiple sclerosis (MS) research and highlight some of the current challenges and prospective for generating novel therapeutic treatments for MS patients.",

author = "\{Di Ruscio\}, A. and F. Patti and Welner, \{R. S.\} and Tenen, \{D. G.\} and G. Amabile",

year = "2015",

month = jul,

day = "1",

doi = "10.1038/cddis.2015.179",

language = "English",

volume = "6",

journal = "Cell Death and Disease",

issn = "2041-4889",

publisher = "Springer Nature",

number = "7",

}

TY - JOUR

T1 - Multiple sclerosis

T2 - Getting personal with induced pluripotent stem cells

AU - Di Ruscio, A.

AU - Patti, F.

AU - Welner, R. S.

AU - Tenen, D. G.

AU - Amabile, G.

PY - 2015/7/1

Y1 - 2015/7/1

N2 - Human induced pluripotent stem (iPS) cells can be derived from lineage-restricted cells and represent an important tool to develop novel patient-specific cell therapies and research models for inherited and acquired diseases. Recently, patient-derived iPS cells, containing donor genetic background, have offered a breakthrough approach to study human genetics of neurodegenerative diseases. By offering an unlimited source of patient-specific disease-relevant cells, iPS cells hold great promise for understanding disease mechanisms, identifying molecular targets and developing phenotypic screens for drug discovery. This review will discuss the potential impact of using iPS cell-derived models in multiple sclerosis (MS) research and highlight some of the current challenges and prospective for generating novel therapeutic treatments for MS patients.

AB - Human induced pluripotent stem (iPS) cells can be derived from lineage-restricted cells and represent an important tool to develop novel patient-specific cell therapies and research models for inherited and acquired diseases. Recently, patient-derived iPS cells, containing donor genetic background, have offered a breakthrough approach to study human genetics of neurodegenerative diseases. By offering an unlimited source of patient-specific disease-relevant cells, iPS cells hold great promise for understanding disease mechanisms, identifying molecular targets and developing phenotypic screens for drug discovery. This review will discuss the potential impact of using iPS cell-derived models in multiple sclerosis (MS) research and highlight some of the current challenges and prospective for generating novel therapeutic treatments for MS patients.

UR - https://www.scopus.com/pages/publications/84954322927

U2 - 10.1038/cddis.2015.179

DO - 10.1038/cddis.2015.179

M3 - Review article

SN - 2041-4889

VL - 6

JO - Cell Death and Disease

JF - Cell Death and Disease

IS - 7

M1 - e1806

ER -

Multiple sclerosis: Getting personal with induced pluripotent stem cells

Abstract

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this